SCHEMBL3198327

SCHEMBL3198327

O=C1c2cccc(O)c2C(=O)c2c(O)ccc(O)c21

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 6/20 0.86
MAPT P10636 9/20 0.83
TDP1 Q9NUW8 6/20 0.83
ALDH1A1 P00352 6/20 0.83
HPGD P15428 6/20 0.83
MAPK1 P28482 5/20 0.83
ALOX15 P16050 5/20 0.83
HSD17B10 Q99714 5/20 0.83
SMN1; SMN2 Q16637 5/20 0.83
TSHR P16473 3/20 0.83
LMNA P02545 2/20 0.83
MAOB P27338 2/20 0.83
HTT P42858 1/20 0.83
KMT2A Q03164 9/20 0.71
MEN1 O00255 8/20 0.71
CSNK2A2 P19784 2/20 0.69
CSNK2B P67870 2/20 0.69
CSNK2A1 P68400 2/20 0.69
CSNK2A3 Q8NEV1 2/20 0.69
EGFR P00533 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30695844 1.00 MAOA (0.86) MAOAMAPTTDP1ALDH1A1HPGD
1-Hydroxyanthraquinone SCHEMBL9317010 0.94 MAPT (0.80) MAOAMAPTTDP1ALDH1A1HPGD
Danthron SCHEMBL9317014 0.94 MAPT (0.80) MAOAMAPTTDP1ALDH1A1HPGD
Anthrarufin SCHEMBL11422341 0.93 MAPT (0.83) MAOAMAPTTDP1ALDH1A1HPGD
Anthrarufin SCHEMBL29874705 0.93 MAOA (1.00) MAOAMAPTTDP1ALDH1A1HPGD
Anthrarufin SCHEMBL29363946 0.93 MAOA (1.00) MAOAMAPTTDP1ALDH1A1HPGD
Anthrarufin SCHEMBL187843 0.93 MAOA (1.00) MAOAMAPTTDP1ALDH1A1HPGD
Anthrarufin SCHEMBL28419741 0.91 MAOA (0.95) MAOAMAPTTDP1ALDH1A1HPGD
Danthron SCHEMBL30544826 0.91 MAPT (1.00) MAOAMAPTTDP1ALDH1A1HPGD
Danthron SCHEMBL29356886 0.91 MAPT (1.00) MAOAMAPTTDP1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP claimed
CN-115537013-B Nuclear radiation resistant polyurethane elastomer material and preparation method thereof 中国人民解放军海军工程大学 2024-03-29 CN claimed
CN-115537013-A Nuclear radiation resistant polyurethane elastomer material and preparation method thereof 中国人民解放军海军工程大学 2022-12-30 CN claimed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
CN-115537013-B Nuclear radiation resistant polyurethane elastomer material and preparation method thereof 中国人民解放军海军工程大学 2024-03-29 CN disclosed
CN-107847466-B Formulations and methods for modulating wound healing 贝欧曼蒂克丝公司 2024-02-06 CN disclosed
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 US disclosed
CN-115537013-A Nuclear radiation resistant polyurethane elastomer material and preparation method thereof 中国人民解放军海军工程大学 2022-12-30 CN disclosed
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
US-11142827-B2 Fluoride-free zirconium-based metal pre-treatment for passivation HENKEL AG & CO. KGAA (DE) 2021-10-12 US disclosed
US-20210228501-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2021-07-29 US disclosed
US-4746461-A Method for preparing 1,4-diaminoanthraquinones and intermediates thereof THE CLOROX COMPANY (US) 1988-05-24 US disclosed
US-4661293-A Method for preparing 1,4-diaminoanthraquinones and intermediates thereof THE CLOROX COMPANY (US) 1987-04-28 US disclosed
EP-0159357-A4 CARMINOMYCINONE PRECURSORS AND ANALOGUES AND DERIVATIVES THEREOF. UNIV MELBOURNE (AU) 1986-04-15 EP disclosed
EP-0159357-A1 CARMINOMYCINONE PRECURSORS AND ANALOGUES AND DERIVATIVES THEREOF. UNIV MELBOURNE (AU) 1985-10-30 EP disclosed
WO-1985001726-A1 CARMINOMYCINONE PRECURSORS AND ANALOGUES AND DERIVATIVES THEREOF THE UNIVERSITY OF MELBOURNE (AU) 1985-04-25 WO disclosed
US-4147706-A Intermediates for polycyclic quinonoid antibiotics RESEARCH CORPORATION (US) 1979-04-03 US disclosed
US-4070382-A DAUNOMYCINS, ANTITUMOR AGENTS RESEARCH CORPORATION (US) 1978-01-24 US disclosed
US-4012284-A STREPTOMYCES Societa' Farmaceutici Italia, S.p.A. (IT) 1977-03-15 US disclosed
US-3971740-A DYES FOR POLYESTER FIBERS CIBA-GEIGY AG (CH) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB MAOA 4700/4885MAPT 3534/4885TDP1 1811/4885
US-20210228501-A1 Formulation and Process for Modulating Wound Healing ATG7, SQSTM1, ATF4 MAOA 4389/4885MAPT 3091/4885TDP1 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.